[Considerations on delocalized HbA1c assays].
Availability and knowledge of HbA(1c) value during consultation is an important feature for diabetologists, that permits a better adaptation of therapy and a better motivation of patients. This expectation explains the request for delocalized assays of HbA(1c), even though life prognosis is not affected, like in the other cases of point of care testing. One of the most frequent solutions is the use of immunological delocalized HbA(1c) assays. Technically, these methods have to meet the same criteria as those used in laboratories. They have to be standardized, and controlled according to the "Guide de Bonne Exécution des Analyses de Biologie Médicale" (GBEA) rules. Solutions chosen for delocalization must respect specific skills of clinicians and biologists and cope with cost limitations. This paper reviews rationales for delocalized HbA(1c) assays, steps of their implementation, and their use in practical routine, with a special emphasis given on the necessary complementarity between clinicians and biologists.
Bordas-Fonfrède
M
M
Laboratoire Central de Biochimie, Groupe Hospitalier Pitié-Salpêtrière, Paris.
Sélam
J
J
Goudable
J
J
Thivolet
C
C
Vialettes
B
B
Chapelle
J
J
Drouin
P
P
Hue
G
G
Lévy-Marchal
C
C
Slama
G
G
Gillery
P
P
D015415:Biomarkers / Q000097:blood; D001774:Blood Chemical Analysis / Q000379:methods / Q000592:standards; D003920:Diabetes Mellitus / Q000097:blood*; D006442:Glycated Hemoglobin / Q000032:analysis*; D006801:Humans; D011785:Quality Assurance, Health Care
D015415:Biomarkers; D006442:Glycated Hemoglobin